Role of Histone Acetylation in the Development of Diabetic Retinopathy and the Metabolic Memory Phenomenon

Qing Zhong and Renu A. Kowluru*

Department of Ophthalmology, Wayne State University, Detroit, Michigan

ABSTRACT

Hyperglycemia is considered as one of the major determinants in the development of diabetic retinopathy, but the progression of retinopathy resists arrest after hyperglycemia is terminated, suggesting a metabolic memory phenomenon. Diabetes alters the expression of retinal genes, and this continues even after good glycemic control is re-instituted. Since the expression of genes is affected by chromatin structure that is modulated by post-translational modifications of histones, our objective is to investigate the role of histone acetylation in the development of diabetic retinopathy, and in the metabolic memory phenomenon. Streptozotocin-induced rats were maintained either in poor glycemic control (PC, glycated hemoglobin, GHb >11%) or good glycemic control (GC, GHb <6%) for 12 months, or allowed to be in PC for 6 months followed by in GC for 6 months (PC-GC). On a cellular level, retinal endothelial cells, the target of histone acetyltransferase (HAT), and histone acetylation were quantified. Hyperglycemia activated HDAC and increased HDAC1, 2, and 8 gene expressions in the retina and its capillary cells. The activity HAT was compromised and the acetylation of histone H3 was decreased. Termination of hyperglycemia failed to provide any benefits to diabetes-induced changes in retinal HDAC and HAT, and histone H3 remained subnormal. This suggests "in principle" the role of global acetylation of retinal histone H3 in the development of diabetic retinopathy and in the metabolic memory phenomenon associated with its continued progression. J. Cell. Biochem. 110: 1306–1313, 2010. © 2010 Wiley-Liss, Inc.

KEY WORDS: DIABETIC RETINOPATHY; HISTONE ACETYLATION; HISTONE DEACETYLASE; METABOLIC MEMORY

iabetic retinopathy, a microvascular complication, is the leading cause of acquired blindness in young adults. Many biochemical and molecular sequelae of hyperglycemia have been implicated in its pathogenesis [Kowluru, 2005a; Kowluru and Chan, 2007; Madsen-Bouterse and Kowluru, 2008], but the exact mechanism has still remained elusive. Intensive glycemic control can prevent/inhibit the development and progression of retinopathy in patients with diabetes [Diabetes Control and Complications Trial Research Group, 1993], and the benefits of intensive control persist for some time even after it is terminated suggesting a "metabolic memory" phenomenon [Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group, 2000, 2008]. We have shown that the retina continues to experience increased oxidative damage even when hyperglycemic insult is terminated in rats, and proteins continue to be oxidatively modified [Kowluru, 2003; Kowluru et al., 2007]. However, the mechanism responsible for this metabolic memory remains unclear.

The expressions of various genes, which are important in retinal dysmetabolism in diabetes, including manganese superoxide dismutase (MnSOD), interleukin-1B, connexin, etc., are altered in the retina in diabetes [Joussen et al., 2001; Kowluru et al., 2003; Kowluru and Odenbach, 2004; Navaratna et al., 2007; Kowluru and Kanwar, 2009; Li and Roy, 2009; Kowluru and Chan, 2010]. Epigenetic modulation of chromatin, including histone acetylation, methylation, phosphorylation, are important mechanisms in regulating gene transcription [Vaissière et al., 2008; Delcuve et al., 2009]. Acetylation/deacetylation of histones allows access of the transcription factors for DNA binding and gene transcription, and the steady-state levels of histone acetylation are maintained by a balance between the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Deregulation of histone acetylation/deacetylation and other epigenetic modulations have been implicated in many pathological conditions including cancer and multiple sclerosis [Yang, 2004; Bonnefil et al., 2008; Hitchler et al., 2008]. How they

Grant sponsor: National Institutes of Health; Grant number: EY017733; Grant sponsor: Juvenile Diabetes Research Foundation; Grant number: JDRF-1-2008-764; Grant sponsor: The Thomas Foundation; Grant sponsor: Research to Prevent Blindness.

*Correspondence to: Dr. Renu A. Kowluru, Kresge Eye Institute, 4717 St. Antoine, Detroit, MI 48201. E-mail: rkowluru@med.wayne.edu

Received 8 December 2009; Accepted 2 April 2010 • DOI 10.1002/jcb.22644 • © 2010 Wiley-Liss, Inc. Published online 1 June 2010 in Wiley InterScience (www.interscience.wiley.com).

1306

contribute to the development of diabetic retinopathy remains to be explored.

Recent studies have shown that high glucose exposure of aortic endothelial cells induces epigenetic changes in the promoter of NFκB subunit p65 [El-Osta et al., 2008], and modification of histone H3 at lysine 9 (H3K9) at the proximal Cox2 promoter bearing the NF-KB binding site is shown to modulate hyperglycemia-induced thioredoxin interacting protein-mediated inflammation in retinal capillary endothelial cells [Perrone et al., 2009]. Furthermore, epigenetic modifications of histones are considered to play a major underlying role in the "metabolic memory" phenomenon [Villeneuve et al., 2008]. Our recent studies have shown that diabetesinduced alterations in retinal genes (e.g., upregulation or suppression) do not reverse and apoptosis continues after hyperglycemia is terminated [Kowluru et al., 2007; Kanwar and Kowluru, 2009; Kowluru and Chan, 2010; Kowluru and Kanwar, 2010; Madsen-Bouterse et al., 2010]. The objective of this study is to examine the role of histone modification in the development of diabetic retinopathy and in the resistance of retinopathy to arrest after termination of hyperglycemia. Using rat model of diabetic retinopathy and metabolic memory, we have investigated histone acetylation in the retina of rats diabetic for 12 months, or in poor glycemic control for 6 months followed by good glycemic control for 6 additional months. Since the retina is a complex tissue; key findings were confirmed in in vitro system using isolated retinal endothelial cells, the cells that are the target of histopathology characteristic of diabetic retinopathy.

METHODS

RATS

Wistar rats (male, 200 g) were randomly assigned to normal or diabetic groups and diabetes was induced with streptozotocin (55 mg/kg body weight). Diabetic rats were either allowed to remain in poor metabolic control for 12 months (PC), or maintained in good metabolic control for the entire duration of 12 months (GC), or were maintained in poor metabolic control for 6 months, followed by good metabolic control for 6 additional months (PC-GC). The rats in which poor metabolic control was intended received 1-2 IU insulin 4–5 times a week to prevent ketosis and weight loss, and the rats in which good metabolic control was intended received insulin twice daily (5-7 IU total) to maintain a steady gain in body weight and urine glucose values below 150 mg/24 h [Kanwar and Kowluru, 2009]. Each group had 10 or more rats. At the end of the desired duration of metabolic control, the animals were sacrificed, and retina were immediately isolated. Treatment of animals conformed to the Association for Research in Vision and Ophthalmology's Resolution on Treatment of Animals in Research (National Institutes of Health) and the institutional guidelines.

ISOLATED RETINAL ENDOTHELIAL CELLS

Retinal endothelial cells were prepared from bovine retina, and were cultured to 80% confluence on plates coated with 0.1% gelatin. The culture medium consisted of Dulbecco's modified Eagle's medium containing 15% fetal calf serum (heat inactivated), 5% replacement serum (Nu-serum; BD Bioscience, San Jose, CA), heparin (50 μ g/ml), endothelial growth supplement (25 μ g/ml), and antibiotic/antimycotic in an environment of 95% O₂ and 5% CO₂ [Kowluru et al., 2006]. Cells from passage 5th–6th were incubated in 5 mM glucose or 20 mM glucose media for 4 days, and at the end of the incubation, cells were trypsinized and nuclear fraction was prepared by differential centrifugation, as given below.

NUCLEAR FRACTION

Nuclear extract was prepared using the Nuclear Extract Kit (Active Motif, Carlsbad, CA) following manufacturer's protocol. In brief, retina or cells were homogenized in hypotonic buffer, and was centrifuged at 1,000 rpm for 10 min. The pellet was suspended in hypotonic buffer and centrifuged at 13,000 rpm for 30 s. The pellets were re-suspended in complete lysis buffer, incubated at 4°C for 30 min, and centrifuged at 13,000 rpm for 10 min. The supernatant was used as the "nuclear" fraction.

ACTIVITY OF HDAC AND HAT

HDAC activity was measured by a non-isotopic assay that uses a fluorescent derivative of epsilon-acetyl lysine (HDAC Fluorescent Activity Assay Kit from Upstate, Lake Placid, NY). Briefly, in a total reaction mixture of 30 μ l, nuclear protein (1–25 μ g) was mixed with HDAC assay substrate, and incubated at 37°C for 30 min, followed by mixing with the activator solution. The fluorescence was read in SpectraMax M2 Microplate Reader (Molecular Devices, Sunnyvale, CA) with excitation of 360 nm and emission of 460 nm.

Activity of HAT was quantified in the nuclear fraction by nonradioactive indirect ELISA kit from Millipore (Lack Placid, NY). The plate was coated with biotinylated histone H3 or H4 peptide, rinsed and blocked with 3% BSA for 30 min. After washing the wells, 0– 10 μ g of nuclear protein was incubated with acetyl-CoA and Na butyrate (HDAC inhibitor). The wells were washed and the samples were incubated with anti-acetyl-lysine antibody. This was followed by washing and incubation with anti-rabbit IgG conjugated with horseradish peroxidase. The final incubation was with tetramethylbenzidine substrate mixture for 5–10 min, and the reaction was stopped by sulfuric acid. The readings were monitored at 450 nm with a reference wavelength of 570 nm. For acetylated histone H3, the linear range was 10–75 ng, and for acetylated histone H4, the range was 1–7.5 ng.

QUANTIFICATION OF ACETYLATED HISTONE H3 BY ELISA

Acetylated histone H3 level was quantified in the nuclear fraction by solid phase sandwich ELISA using PathScan[®] Acetylated histone H3 Sandwich ELISA kit (Cell Signaling, Beverly, MA). Briefly, $0-2.0 \mu g$ nuclear extract was incubated for 2 h in histone H3 antibody-coated microplates. After rinsing, the samples were incubated with acetylated-lysine mouse monoclonal antibody. The unbound antibody was washed, and this was followed by incubation with enzyme-linked (HRP) anti-mouse IgG. After incubating the samples with the HRP substrate for 5 min, the reaction was terminated by the stop solution. The intensity of the color was measured at 450 nm, within 30 min of termination. The experiment was performed in duplicate to ensure reproducibility.

GENE EXPRESSION

Total RNA was extracted from the nuclear fraction with Trizol reagent (Invitrogen, Carlsbad, CA). cDNA was synthesized by High Capacity cDNA Reverse Transcription Kit (Applied Biosystem, Foster City, CA) and amplified by PCR. The PCR primers for rat were: HDAC1 forward: 5'-GTT CTT GCG TTC TAT TCG CC-3' and reverse: 5'-TGT CCG TCT GCT GCT TAT TG-3'; HDAC2 forward: 5'-TCA ACT TTC CCA TGA GGG AC-3' and reverse: 5'-GTT AGG TTG AAG CAG CCC AG-3'; HDAC8 forward: 5'-CGC TAC CCC CGG TTT ATA TT-3' and reverse: 5'-CCT TCT TGG CTG ACC TTC TG-3': and B-actin forward: 5'-CCT CTA TGC CAA CAC AGT GC-3' and reverse: 5'-CAT CGT ACT CCT GCT TGC TG-3'. Bovine primers used were: HDAC1 forward: GCC ATC CCC GAG GAC GCC AT and reverse: TTC TTG CGC CCG CCT TCT CC: HDAC2 forward: TCC GCC TTC ACC CCA GCC TT and reverse: GCC GCC TCC TTG ACT GTA CGC; HDAC8 forward: GGA GCA GGA ACC CGA GCC CA and reverse: GGC CAG GGA GTC GCA CAC G. PCR conditions included initial denaturation at 95°C for 2 min followed by 35 cycles at 92°C for 1 min, annealing at 50°C for 2 min, extension at 72° C for 1 min, and a final extension at 72° C for 7 min. PCR products were electrophoresed on 1.2% agarose gel and imaged by Benchtop 3UV Transilluminator (UVP, Inc., Upland, CA). Quantitative analysis was achieved by measuring the integrated density value of PCR products in gel photographs using Un-Scan-It Gel digitizing software [Madsen-Bouterse et al., 2010].

Gene expression of HDACs was also confirmed using quantitative real-time PCR (RT-PCR). RT-PCR was performed using 90 ng cDNA template in 96-well plates using the ABI-7500 sequence detection system and TaqMan primers using β-actin (rat) or 18s (bovine) as housekeeping control. Genbank accession numbers of TaqMan primers for rat HDAC1, rat HDAC2, rat HDAC8, rat β -actin, bovine HDAC1, bovine HDAC8 and 18S rRNA are NM_001025409.1, NM_053447.1, NM_001126373.1, NM_031144.2, NM_001037444.1, NM_001075146.1, and X03205.1, respectively. Each sample was measured in triplicate. Fold change in mRNA abundance was calculated with the ddCt method as routinely used by us [Kowluru and Chan, 2010; Madsen-Bouterse et al., 2010].

WESTERN BLOTTING

For quantifying acetylation of histones 15–30 μg of retinal or cell homogenate was analyzed by Western blot using primary antibodies against acetylated histone H3 (Abcam, Cambridge, MA) and total histone H3 (Cell Signaling). The band intensity was quantified using Un-Scan-It Gel digitizing software (Silk Scientific, Inc., Orem, UT).

STATISTICAL ANALYSIS

Data are expressed as mean \pm standard deviation. Statistical analysis was performed using the non-parametric Kruskal–Wallis test followed by Mann–Whitney *U*-test. *P* < 0.05 was considered statistically significant.

RESULTS

The average body weight of the rats in poor glycemic control was significantly lower (PC = 290 g and normal = 550 g), and their GHb

values were over twofold higher (>11.5% and 5.5%) compared to the age-matched normal control rats. The rats that were maintained in good glycemic control for the entire duration (GC group) had similar body weight (520 g) and GHb values (5.7%) as their agematched normal rats (P > 0.05). However, the rats in PC-GC group had their body weight and GHb values before initiation of good glycemic control (310 g and 12%) that were not different from the rats in PC group, but these values became similar to those in normal group after initiation of good glycemic control.

Poor glycemic control for 12 months activated HDAC by over threefold in the retinal nuclear fraction (Fig. 1a), and the gene expressions of HDAC1, HDAC2, and HDAC8 were elevated by 70–90% compared to the values obtained from age-matched normal rats (Fig. 1b,c). In the same diabetic rats, the activity of the enzyme responsible for acetylating histones H3 was decreased by 30% in the nuclear fraction, but the enzyme responsible for acetylation of histone H4 remained unchanged (Fig. 2a,b). The amount of total acetylated histone H3, as determined by solid phase ELISA (Fig. 3a) or by Western blot technique (Fig. 3b), was decreased by about 20–30% in diabetes compared to the values obtained from normal rats (P < 0.05 vs. normal).

Re-institution of good glycemic control after 6 months of poor glycemic control (PC-GC group) failed to protect retinal nucleus from increases in the activity of HDAC and gene expressions of HDAC1, HDAC2, and HDAC8 (Fig. 1). In addition, the activity of HAT also remained compromised with reduced levels of acetylated histone H3 (Figs. 2 and 3). Although the extent of alterations in HDAC and HAT activities in the PC-GC group is higher compared to the values obtained in PC group, these values did not achieve any statistical significance.

However, when good glycemic control was initiated soon after induction of diabetes (GC group), activation of HDAC and inhibition of HAT was prevented (Figs. 1–3) suggesting that the effect of good glycemic control on various parameters in PC-GC group animals is not influenced by the high insulin dose administered to maintain the glycemic control, and further strengthen the importance of early and sustained good glycemic control for diabetic patients.

Since the retina is a multi-layered sensory tissue that has many cell types, in order to specifically understand the role of histone acetylation in the development of vascular pathology of diabetic retinopathy, key experiments were performed in endothelial cells isolated from the retina. As shown in Figure 4a, the activity of HDAC was increased by over 40% in the nuclear fractions of the cells incubated in high glucose compared to normal glucose, with concomitant increases in the gene expressions of HDAC1, HDAC2, and HDAC8 as observed by both conventional and quantitative PCR measurements (Fig. 4b,c). In the same cell preparations, high glucose exposure also reduced the amount of total acetyl histone H3 as quantified by ELISA (Fig. 5a), or by its protein expression (Fig. 5b).

DISCUSSION

This is the first study demonstrating alterations in the global acetylation of retinal histones in diabetes. Activity of HDAC activity and its gene transcripts are increased, and HAT activity is decreased,



Fig. 1. Diabetes activates HDAC in the retina and elevates its gene expression. (a) The activity of retinal HDAC was measured using HDAC Fluorescent Activity Assay Kit, and the gene expression of HDAC1, HDAC2, and HDAC8 was quantified by (b) conventional PCR using the primers provided in the method section, or (c) real-time quantitative PCR using TaqMan primers. β -actin was used as a housekeeping control. Figure represents expression of the HDAC adjusted to that of β -actin in the same sample. Each measurement was made in duplicate or triplicate. The values are represented as mean \pm SD of 5–7 rats in each of the four groups. Norm = normal, PC = poor control for 12 months, PC-GC = poor control for 6 months followed by good control for 6 additional months, GC = good control for entire 12 months. **P* < 0.05 compared to normal.

resulting in the reduced acetylation of histone H3. On a cellular level, high glucose exposure of the cells that are the targets of pathology associated with diabetic retinopathy, the endothelial cells, also show increases in HDAC activity and its transcripts, and decrease in acetylated histone H3, suggesting that histone acetylation has an important role in the development of diabetic retinopathy. Reversal of hyperglycemia for 6 months in diabetic rats, which our previous studies have shown to provide no benefit to



Fig. 2. Diabetes inhibits retinal HAT activity. The activity of HAT was quantified in the nuclear fraction by an ELISA method using either acetylated histone H3 or histone H4. Each measurement was made in duplicate in 5–6 rats in each group.

retinal capillary cell apoptosis and the development of histopathology [Kowluru et al., 2007; Kowluru and Chan, 2010], also fails to provide any benefit to the retinal histone acetylation and the enzymes responsible for maintaining acetylation homeostasis. This strongly suggests that histone acetylation is an important contributor in the progression of diabetic retinopathy after hyperglycemia is terminated.

Histones are important in the regulation of gene expressions, and post-translational modifications of histones regulate transcription and genome stability [Bhaumik et al., 2007]. Acetylation of histones activates gene transcriptional activity [Vaissière et al., 2008; Delcuve et al., 2009], and HDACs remove acetyl groups potentially inhibiting the expression of genes regulated by that portion of DNA. These covalent modifications, by altering chromatin structure affect DNA regulatory processes including replication, repair, and transcription [Haberland et al., 2009]. Here we show that the activity of HDAC is increased in the retina in diabetes, while that of HAT is decreased, this is supported by reports showing diabetes-induced increase HDAC activity in the kidney and in cardiac tissue, the tissues that are associated with micro- and macro-vascular complications, respectively [Dong and Ren, 2007; Lee et al., 2007; Noh et al., 2009]. A number of acetyltransferases with different HAT complexes acetylate histones, and regulate different levels/ stages of transcription or other nuclear processes [Shahbazian and Grunstein, 2007]. Acetylation of histone H3 is important in cell cycle progression, and that of histone H4 in viability [Howe et al., 2001]. Our results show that the activity of histone H3 acetyltransferase is decreased in diabetes, but that of histone H4 acetyltransferase is







Fig. 4. Exposure of retinal endothelial cells to high glucose activates HDAC activity and increases their gene transcripts. a: HDAC activity was quantified in the cell incubated in 5 or 20 mM glucose for 4 days by Fluorescent Activity Assay Kit, and the gene expressions for HDAC1, HDAC2, and HDAC8 were quantified by (b) conventional PCR using bovine primers, β -actin was used as the housekeeping gene, or (c) real-time quantitative PCR using bovine (made to order) TaqMan primers. 18s was used as a housekeeping control. Figure represents expression of HDACs adjusted to that of the housekeeping protein in the same sample. Each measurement was made in duplicate. The values are represented as mean \pm SD obtained from three or more different cell preparations. 5 mM = 5 mM glucose, 20 mM = 20 mM glucose; **P* < 0.05 compared to 5 mM glucose.

not affected; however, the reason for such divergent results is not clear.

Reactive oxygen species (ROS) are shown to increase HDAC activity and decreases HAT activity, and inhibit histone acetylation [Kang et al., 2005; Berthiaume et al., 2006]. In diabetes, retina and its capillary cells experience increased oxidative stress [Kowluru et al., 2001; Kowluru, 2005b], and hyperglycemia-induced super-oxide overproduction activates the major pathways that are considered important in the development of diabetic retinopathy

[Brownlee, 2005; Kanwar and Kowluru, 2009]. Thus, the plausible mechanism by which diabetes regulates retinal HDAC and HAT could include increased oxidative stress. HDAC activity is also stimulated by ischemia and hypoxia [Endres et al., 2000; Granger et al., 2008; Ellis et al., 2009]. Hypoxia is considered as the major stimulus for retinal neovascularization observed in diabetes [Frank, 2004], and the contribution of increased retinal hypoxia in diabetes in the activation of retinal HDAC remains a strong possibility.





Alterations in retinal HDAC and HAT activities in diabetes are accompanied by decreased levels of total acetylated histone H3, and this is also observed at duration of diabetes when histopathology of diabetic retinopathy are observed [Mizutani et al., 1996; Kern et al., 2000]. The level of acetylated H3K9 in promoter regions is shown to strongly correlate with gene expression [Suzuki et al. 2008]. This suggests that deacetylation of histone H3 could be contributing to the altered expressions of the genes implicated in the development of diabetic retinopathy. In support, our in vitro data show similar phenomenon in retinal endothelial cells incubated in high glucose. Although hyperglycemia-induced increase in HDAC activity in the whole retina was about threefold compared to 40% in isolated endothelial cells, the reason for this could be the whole retina represents contribution from multiple cells and raises the possibility that the extent of increase in HDAC is much larger in non-vascular cells than the vascular cells. The expression of many retinal genes, including genes involved in maintaining redox status and apoptosis are altered in diabetes [Joussen et al., 2001; Kowluru et al., 2003; Navaratna et al., 2007; Kowluru and Kanwar, 2009; Li and Roy, 2009; Kowluru and Chan, 2010; Madsen-Bouterse et al., 2010]. The global deacetylation of histone H3 may possibly be related to downregulation of these genes, and the reduction of histone acetylation, via repressing gene transcription, could be contributing to the accelerated retinal cell loss seen in diabetic retinopathy.

The retina continues to experience increased oxidative damage, and capillary cell apoptosis and histopathology characteristic of diabetic retinopathy do not halt after hyperglycemic insult is terminated in rats for at least 6 months [Kowluru, 2003; Kowluru et al., 2007; Kanwar and Kowluru, 2009; Kowluru and Chan, 2010; Kowluru and Kanwar, 2010; Madsen-Bouterse et al., 2010]. Here we show that the termination of poor glycemic control for 6 months does not protect retinal nucleus from alterations in the activities of both HDAC and HAT, and the levels of acetylated histone H3 and H3K9 remain compromised, suggesting that histone modifications are important in the metabolic memory phenomenon associated with the continued progression of diabetic retinopathy. In support, epigenetic histone modification is considered as a major underlying mechanism for sustained proinflammatory phenotype of diabetic cells [Villeneuve et al., 2008]. Histone modifications, such as methylation of H3K9 and H3K4, are related with persistent activation of inflammation genes after transient high glucose [El-Osta et al., 2008; Reddy et al., 2008; Villeneuve et al., 2008]. This raises the possibility that the persistent alterations in acetylation of histone may cause continuous changes in the genes that are important in the development and progression of diabetic retinopathy.

Thus, in summary, our study shows "in principle" the role of global acetylation of retinal histone H3 in the development of diabetic retinopathy and in the metabolic memory phenomenon associated with its resistance to reverse after termination of hyperglycemia, and paves path for future studies to explore the mechanism via which this acetylation could contribute to the pathogenesis of diabetic retinopathy.

ACKNOWLEDGMENTS

Authors thank Dr. Srirupa Das for her help in the initial work, and Mamta Kanwar and Yakov Shamailov for technical assistance.

REFERENCES

Berthiaume M, Boufaied N, Moisan A, Gaudreau L. 2006. High levels of oxidative stress globally inhibit gene transcription and histone acetylation. DNA Cell Biol 25:124–134.

Bhaumik SR, Smith E, Shilatifard A. 2007. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 14:1008–1016.

Bonnefil PC, Pandozy G, Mastronardi F. 2008. Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: A contribution to the current debate on disease pathogenesis. Prog Neurobiol 86:368–378.

Brownlee M. 2005. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54:1615–1625.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. 2000. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381–389.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. 2008. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 126:1707–1715.

Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986.

Delcuve GP, Rastegar M, Davie JR. 2009. Epigenetic control. J Cell Physiol 219:243–250.

Dong F, Ren J. 2007. Fidarestat improves cardiomyocyte contractile function in db/db diabetic obese mice through a histone deacetylase Sir2-dependent mechanism. J Hypertens 25:2138–2147.

Ellis L, Hammers H, Pili R. 2009. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 250:145–153.

El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. 2008. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205:2409–2417.

Endres M, Meisel A, Biniszkiewicz D, Namura S, Prass K, Ruscher K, Lipski A, Jaenisch R, Moskowitz NA, Dirnagl U. 2000. DNA methyltransferase contributes to delayed ischemic brain injury. J Neurosci 20:3175–3181.

Frank RN. 2004. Diabetic retinopathy. N Engl J Med 350:48-58.

Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, Epstein JA, Gruber PJ. 2008. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 22:3549–3560.

Haberland M, Montgomery RL, Olson EN. 2009. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 10:32–42.

Hitchler MJ, Oberley LW, Domann FE. 2008. Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells. Free Radic Biol Med 45:1573–1580.

Howe L, Auston D, Grant P, John S, Cook RG, Workman JL, Pillus L. 2001. Histone H3 specific acetyltransferases are essential for cell cycle progression. Genes Dev 15:3144–3154.

Joussen AM, Huang S, Poulaki V, Camphausen K, Beecken WD, Kirchhof B, Adamis AP. 2001. In vivo retinal gene expression in early diabetes. Invest Ophthalmol Vis Sci 42:3047–3057.

Kang J, Chen J, Shi Y, Jia J, Zhang Y. 2005. Curcumin-induced histone hypoacetylation: The role of reactive oxygen species. Biochem Pharmacol 69:1205–1213.

Kanwar M, Kowluru R. 2009. Role of glyceraldehyde 3-phosphate dehydrogenase in the development and progression of diabetic retinopathy. Diabetes 58:227–234. Kern TS, Tang J, Mizutani M, Kowluru R, Nagraj R, Lorenzi M. 2000. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: Comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 41:3972–3978.

Kowluru RA. 2003. Effect of re-institution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 52:818–823.

Kowluru RA. 2005a. Diabetic retinopathy, oxidative stress and antioxidants. Curr Top Nutraceutical Res 3:209–218.

Kowluru RA. 2005b. Diabetic retinopathy: Mitochondrial dysfunction and retinal capillary cell death. Antioxidants Redox Signal 7:1581– 1587.

Kowluru RA, Chan PS. 2007. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007:43603.

Kowluru RA, Chan PS. 2010. Metabolic memory in diabetes–From in vitro oddity to in vivo problem: Role of apoptosis. Brain Res Bull 81:297–302.

Kowluru RA, Kanwar M. 2009. Oxidative stress and the development of diabetic retinopathy: Contributory role of matrix metalloproteinase-2. Free Radic Biol Med 46:1677–11685.

Kowluru RA, Kanwar M. 2010. Inflammatory mediators in retinal microvasculature and progression of diabetic retinopathy. Exp Eye Research 90:617–623.

Kowluru RA, Tang J, Kern TS. 2001. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 50:1938–1942.

Kowluru RA, Koppolu P, Chakrabarti S, Chen S. 2003. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res 37:1169–1180.

Kowluru RA, Odenbach. 2004. Role of interleukin-1 β in the development of diabetic retinopathy in rats: Effect of antioxidants. Inves Ophthal Vis Sci 45:4161–4166.

Kowluru RA, Kanwar M, Kennedy A. 2007. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries. Exp Diabetes Res 2007:2196.

Lee HB, Noh H, Seo JY, Yu MR, Ha H. 2007. Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy. Kidney Int Suppl 106:S61–S66.

Li AF, Roy S. 2009. High glucose-induced downregulation of connexin 43 expression promotes apoptosis in microvascular endothelial cells. Invest Ophthalmol Vis Sci 50:1400–1407.

Madsen-Bouterse SA, Kowluru RA. 2008. Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 9:315–327.

Madsen-Bouterse SA, Mohammad G, Kanwar M, Kowluru RA. 2010. Role of Mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxidants & Redox Signaling [Epub ahead of print].

Mizutani M, Kern TS, Lorenzi M. 1996. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 97:2883–2890.

Navaratna D, McGuire PG, Menicucci G, Das A. 2007. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 56:2380–2387.

Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, Lee HB. 2009. Histone deacetylase 2 is a key regulator of diabetes and transforming growth factor-{beta}1-induced renal injury. Am J Physiol Renal Physiol 297:F729–F739.

Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. 2009. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol 221:262–272.

Reddy MA, Villeneuve LM, Wang M, Lanting L, Natarajan R. 2008. Role of the lysine-specific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. Circ Res 103:615–623.

Shahbazian MD, Grunstein M. 2007. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76:75–100.

Suzuki T, Kondo S, Wakayama T, Cizdziel PE, Hayashizaki Y. 2008. Genomewide analysis of abnormal H3K9 acetylation in cloned mice. PLoS ONE 3:e1905.

Vaissière T, Sawan C, Herceg Z. 2008. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 659:40–48.

Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. 2008. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 105:9047–9052.

Yang XJ. 2004. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acid Res 32:959–976.